BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) for use in patients with breast cancer. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients; and BriaDX, its companion diagnostic test. Its preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. has a clinical trial collaboration and supply agreement with Incyte Corporation for developing Bria-IMT with compounds for treating breast cancer. The company is headquartered in West Vancouver, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-9211810
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable
Briacell Therapeutics (CVE:BCT) Frequently Asked Questions
What is Briacell Therapeutics' stock symbol?
Briacell Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BCT."
When is Briacell Therapeutics' next earnings date?
Has Briacell Therapeutics been receiving favorable news coverage?
News headlines about BCT stock have trended neutral this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Briacell Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Briacell Therapeutics.
Who are some of Briacell Therapeutics' key competitors?
Some companies that are related to Briacell Therapeutics include Biotron (BIT), Actinogen Medical (ACW), Rezolute (RZLT), Exopharm (EX1), Rhinomed (RNO), Armata Pharmaceuticals (ARMP), Tissue Regenix Group (TRX), Pharmaust (PAA), Medicenna Therapeutics (MDNA), Immunoprecise Antibodies (IPA), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Nuformix (NFX), Kazia Therapeutics (KZA) and Acrux (ACR).
What other stocks do shareholders of Briacell Therapeutics own?
Who are Briacell Therapeutics' key executives?
Briacell Therapeutics' management team includes the folowing people:
- Dr. William V. Williams M.D., CEO, Pres & Director
- Dr. Charles Louis Wiseman M.D., FACP, Founder & Director
- Mr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 46)
- Ms. Farrah Dean, Mang. of Corp. Devel.
How do I buy shares of Briacell Therapeutics?
Shares of BCT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Briacell Therapeutics' stock price today?
One share of BCT stock can currently be purchased for approximately C$0.04.
How big of a company is Briacell Therapeutics?
What is Briacell Therapeutics' official website?
How can I contact Briacell Therapeutics?
Briacell Therapeutics' mailing address is Bellevue Centre, 235 15th St 3rd Floor, WEST VANCOUVER, BC V7T 2X1, Canada. The company can be reached via phone at +1-604-9211810.
MarketBeat Community Rating for Briacell Therapeutics (CVE BCT)
MarketBeat's community ratings are surveys of what our community members think about Briacell Therapeutics and other stocks. Vote "Outperform" if you believe BCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
